Eye (CNV DMO RVO) Programs in Pharmaceutical Benefits Scheme (PBS) 012-18032900
Expand allThis document outlines details of PBS-subsidised aflibercept, brolucizumab, dexamethasone intravitreal implant, faricimab and ranibizumab for patients with eye conditions.
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Subfoveal choroidal neovascularisation (CNV) quick reference
Diabetic macular oedema (DMO) quick reference
Retinal vein occlusion (RVO) quick reference
Eye program assessing table for CNV
Subfoveal choroidal neovascularisation (CNV) quick reference
Table 1
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB072 form
|
Written Electronic S85: aflibercept brolucizumab faricimab ranibizumab |
No |
OPA |
Must be treated by an:
|
Yes |
|
Grandfather PB377 form |
Written Electronic S85: aflibercept 8 mg/0.07 mL |
No |
OPA |
Must be treated by an: Ophthalmologist Accredited ophthalmology registrar in consultation with an ophthalmologist |
Yes |
|
Continuing |
Streamlined S85: aflibercept faricimab ranibizumab |
No |
N/A |
Must be treated by an:
|
N/A |
|
Continuing |
Telephone Electronic S85: brolucizumab |
No |
OPA |
Must be treated by an:
|
Yes |
Diabetic macular oedema (DMO) quick reference
Table 2
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB155 form
|
Written Electronic S85: aflibercept dexamethasone intravitreal implant faricimab ranibizumab |
No |
OPA |
Must be treated by an:
|
Yes |
|
Grandfather PB378 form |
Written Electronic S85: aflibercept 8 mg/0.07 mL |
No |
OPA |
Must be treated by an:
|
Yes |
|
Continuing |
Streamlined S85: aflibercept dexamethasone intravitreal implant faricimab ranibizumab |
No |
N/A |
Must be treated by an:
|
N/A |
Retinal vein occlusion (RVO) quick reference
Table 3
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB154 form
|
Written Electronic S85: aflibercept dexamethasone intravitreal implant ranibizumab |
No |
OPA |
Must be treated by an:
|
Yes |
|
Continuing |
Streamlined S85: aflibercept dexamethasone intravitreal implant ranibizumab |
No |
N/A |
Must be treated by an:
|
N/A |
Eye program assessing table for CNV
Table 4